The Delhi High Court delivered its judgment in Intra-Cellular Therapies, Inc. versus The Controller of Patents on 6 July 2026, dismissing a patent appeal filed under Section 117A of the Patents Act 1970. Justice Tushar Rao Gedela upheld an order of the Controller of Patents and Designs dated 27 April 2023 that had refused an Indian patent application titled Organic Compounds. The application covered deuterated versions of a known psychiatric drug compound, and the refusal rested on lack of novelty under Section 2(1)(j) and lack of patentability under Section 3(d) of the Act.
Introduction
Struggling to understand Patent Law? Read our complete Patent Law Guide.
This ruling carries weight for pharmaceutical patent practice in India because it reaffirms two doctrines that repeatedly surface in genus and species patent disputes. The first is that a compound covered by a broad genus claim in an earlier patent cannot later be claimed as novel merely because the earlier document did not specifically call it out. The second is that showing a compound behaves better in the bloodstream does not by itself prove the compound treats disease more effectively, which is what Section 3(d) actually demands.
Background of the Application and the Rejection
Intra-Cellular Therapies filed Indian Patent Application number 201817033732 on 7 September 2018 seeking protection for deuterated heterocycle fused gamma carbolines. These compounds were positioned as improved versions of an existing drug molecule referred to in the proceedings as Formula Q, used in treating conditions such as anxiety, psychosis, schizophrenia and sleep disorders. The applicant claimed that replacing certain hydrogen atoms in the molecule with deuterium slowed down the drug’s breakdown in the body and produced more stable blood concentrations over time.
The First Examination Report issued on 31 October 2019 raised technical and formal objections, and the applicant filed a detailed response on 13 February 2020. The Controller then issued two hearing notices before deciding the matter. The first notice, dated 4 February 2022, objected to the claims on the grounds of lack of inventive step and lack of patentability under Section 3(d), but it said nothing about novelty. The second notice, dated 21 February 2023, added an objection under Section 2(1)(j) for the first time. The applicant filed amended claims and written submissions after each hearing, and the Controller ultimately refused the application on 27 April 2023, resting the rejection on three separate grounds covering novelty, inventive step and Section 3(d) of the Act.
The Novelty Objection and the Coverage Versus Disclosure Question
The Controller relied on two prior art documents, described in the proceedings as D1 and D7, both belonging to the same patent family as the subject application and both authored by the same inventor group. D7 disclosed a broad genus formula in which certain positions on the molecule could independently carry hydrogen or deuterium, and the Controller found that specific combinations falling within this genus produced exactly the compounds claimed as Formula I, II and III in the present application. The Controller similarly found that D1 disclosed, through one particular example, the compound claimed as Formula IV.
Counsel for the appellant argued that arriving at the claimed compounds from D1 and D7 required the skilled reader to make several successive selections from a long list of possible substituents, and that a genus disclosure of this kind should not defeat novelty of a specific, later claimed compound. Counsel also pointed out that the European Patent Office, examining the corresponding European application on the very same prior art, had found the claims novel.
The court rejected this line of argument, relying on the Boehringer Ingelheim Pharma judgment of this court, which held that the words covered and disclosed carry the same meaning for the purpose of deciding whether an earlier genus patent anticipates a claim. The court also drew on the Supreme Court’s reasoning in Novartis AG versus Union of India that the scope of a patent must never outrun what it actually discloses, a principle that cuts against permitting the same patentee to first draft a wide genus claim and then seek a fresh patent on individual members of that genus. Since the claimed compounds fell within the scope of D1 and D7, the fact that the earlier documents did not spell out each compound by name made no difference. The court therefore upheld the novelty objection under Section 2(1)(j) for all the claims.
Territoriality, Serial Parenting and the Single Prior Art Question
Two further arguments in the appeal deserve mention even though the court addressed them briefly. The appellant argued that the Controller wrongly treated several prior art documents together as the closest prior art, when established novelty principles call for a single document to serve as the closest reference. Since the court decided novelty on the coverage doctrine, tracing Formula I to III to D7 alone and Formula IV to D1 alone, this particular objection lost most of its force on the facts before the court.
The respondent’s territoriality argument carries wider significance for pharmaceutical patent practice in India. Relying on Communication Components Antenna Inc. versus Ace Technologies Corp., counsel for the Controller argued that patent rights remain strictly territorial, and a grant in a foreign jurisdiction cannot bind the Indian Patent Office even where the foreign examiner considered the identical prior art. The appellant had pointed to the European Patent Office finding the same claims novel over D1 to D7, but the court gave this no independent weight. Applicants who assume a favourable EPO or USPTO outcome will carry persuasive force in India should treat this judgment as a caution against that assumption, particularly where an Indian Controller has independently analysed the same documents and reached the opposite conclusion.
The respondent also raised the concern of serial parenting, pointing out that the inventor behind the cited prior art and the inventor behind the subject application were the same entity. Relying on the Division Bench ruling in AstraZeneca AB versus Intas Pharmaceuticals Ltd., counsel argued that anticipation in such circumstances should be tested against a person in the know rather than an ordinarily skilled person, since an applicant who authors both the genus patent and the later species application cannot plausibly claim ignorance of what the genus already covers.
The court did not need to rest its decision on this heightened standard given its finding on coverage, but the argument still signals that courts remain alert to strategies where an originator patentee seeds a broad genus family early and later attempts to carve out narrower, commercially valuable claims as fresh inventions. Patent portfolios built around a single core molecule, with successive applications for salts, isomers, polymorphs or deuterated variants filed over the years, will likely draw this kind of scrutiny going forward, and applicants would do well to anticipate it rather than be caught off guard by it at the appellate stage.
Section 3(d) and the Limits of Bioavailability Data
The second and more consequential part of the judgment deals with Section 3(d), which bars a patent on a new form of a known substance unless that new form shows enhanced known efficacy, understood in the pharmaceutical context as therapeutic efficacy. The appellant relied heavily on Example 7 of the complete specification, which compared blood concentrations of the deuterated compound against Formula Q in dogs, and on an affidavit that the joint inventor Dr Peng Li filed, containing further mouse and rat data. Both data sets showed that the deuterated compound produced higher and more sustained blood levels of the parent drug and lower levels of certain breakdown products, with one study reporting roughly seventy two percent higher exposure through sublingual dosing.
The court accepted that this data demonstrated a genuine pharmacokinetic difference between the deuterated compound and its parent. It then asked whether that difference amounted to the enhanced therapeutic efficacy Section 3(d) demands. Drawing on the Supreme Court’s efficacy test from Novartis AG and on the Division Bench ruling in Natco Pharma versus Novartis AG, Justice Gedela held that enhanced bioavailability is not synonymous with enhanced therapeutic efficacy, and that any patentee linking the two must establish the connection through specific research data rather than infer it from pharmacokinetic numbers alone. The appellant even submitted a side by side receptor binding study confirming that the deuterated compound and Formula Q behaved in a pharmacologically similar manner, a finding that undercut rather than supported the case for enhanced efficacy. Since no data connected the improved blood exposure to a better clinical outcome for the underlying psychiatric conditions the drug was meant to treat, the court upheld the Section 3(d) objection as well.
The appellant had additionally argued that the Controller ignored Dr Peng Li’s affidavit entirely, in violation of this court’s rulings in Milliken and Company versus Controller of Patents and Designs and The Regents of the University of California versus Union of India. The court chose to examine the affidavit on its own merits instead of remanding the matter on this procedural ground, and having found the data insufficient regardless, held that the outcome would not change.
Because the court had already upheld both the novelty and Section 3(d) objections, it found no need to separately rule on the inventive step objection under Section 2(1)(ja), and it dismissed the appeal with no order as to costs.
Also Read: Bombay HC: Patent Office Must Substantiate Rejections
Conclusion
This judgment sits comfortably within a settled line of Delhi High Court authority on genus and species claims, and it should not surprise practitioners who have followed the AstraZeneca and Boehringer Ingelheim reasoning on coverage versus disclosure. What makes the ruling worth attention is the Section 3(d) analysis, because deuterium switching has become a common strategy for extending protection around ageing drug molecules, and applicants frequently lean on pharmacokinetic data such as improved half life or reduced metabolite formation to argue enhanced efficacy. This judgment draws a firm line against that shortcut, insisting that pharmacokinetic improvement and therapeutic improvement remain two different things unless the patentee proves otherwise. Improved blood exposure or slower breakdown of a drug is a pharmacokinetic property, and the court was right to insist that a patentee show, through dedicated research connecting the pharmacokinetic change to an actual therapeutic benefit, that the drug would treat patients more effectively as a result. Absent that link, courts will keep sending deuterated compound applications back to the same result reached here. Applicants pursuing this strategy in India would do well to build clinical or at least pharmacodynamic evidence of therapeutic benefit into their specifications from the outset rather than relying on exposure data collected for a different purpose.
